News

Nerve growth factor gene therapy delivered safely in Alzheimer’s patients

Publish date: November 21, 2013

 

AT CTAD

The phase 1 study was funded by Ceregene, which was acquired in October 2013 by Sangamo BioSciences.

Dr. Bartus disclosed that he is a consultant for Sangamo BioSciences.

dbrunk@frontlinemedcom.com

Pages

Recommended Reading

Now open: 146 epilepsy clinical trials
MDedge Psychiatry
Extended-release hydrocodone approved by FDA
MDedge Psychiatry
FDA okays flutemetamol for color-enhanced amyloid imaging
MDedge Psychiatry
Pregabalin improves fibromyalgia pain with comorbid depression
MDedge Psychiatry
Fibromyalgia patients may harbor fewer small-nerve fibers
MDedge Psychiatry
Maternal lupus doubled autism risk
MDedge Psychiatry
Number of restless leg movements during sleep may predict AFib progression
MDedge Psychiatry
Head banging: Cause for worry, or normal childhood development?
MDedge Psychiatry
Expanding medication options for pediatric ADHD
MDedge Psychiatry
Small study: TBI leads to rapid deposition of brain amyloid
MDedge Psychiatry